Montefiore Health Program and Albert Einstein College of Medicine announced final Tuesday that they have received a five-year, $111 million grant from the Nationwide Cancer Institute, part of the National Institutes of Health, to lead the particular long-standing AIDS Malignancy Consortium.
The consortium has been a traveling force behind national and worldwide efforts to prevent and treat HIV-related cancers for quarter of a century, Montefiore and Einstein noted.
The work is especially important because antiretroviral therapy to suppress HIV has helped many millions of people live longer and much healthier lives. But the unfortunate consequence associated with living longer with HIV is definitely an increased risk of cancer.
“People living with HIV shoulder a huge burden of cancer, ” stated Dr . Joseph Sparano, associate seat for clinical research in the section of oncology at Montefiore, connect director for clinical research in the Albert Einstein Cancer Center plus principal investigator on the grant, in the statement. “AMC is the only corporation worldwide solely dedicated to the study, therapy and prevention of cancer in this particular group of people. ”
The next phase
The particular AIDS Malignancy Consortium oversees the network of 42 clinical test sites in the U. S., The african continent and Latin America as well as researchers who support its trials, Montefiore and Einstein noted.
It also runs a career program to assist the next generation of leaders in the region receive resources and support. Functions directly with people living with HIV plus cancer to help better identify the requirements of the community.
Comes from its clinical trials have assisted to strengthen treatment guidelines along with advance the prevention and administration of cancers associated with human papillomavirus and the use of precision medicine plus immunotherapy for people living with HIV who else receive antiretroviral therapy, Montefiore plus Einstein said.
“During this next phase, we will build on these types of successes, developing and leading extra clinical trials designed to address one of the most critical needs of people with HIV and cancer, precancerous disease plus individuals at high risk for cancer—most importantly, completing the Anchor test, ” Sparano added.
The Anchor study focuses on the particular prevention and treatment of anal malignancy caused by HPV. Dr . Rebecca Levine, assistant professor of surgery on Einstein and a surgical oncologist with Montefiore, is serving as the Point principal investigator at Einstein plus Montefiore.
“We anticipate the results of this study will have a massive impact on clinical care, ” Levine said in a statement.
The AIDS Malignancy Consortium was once led by the University of Ca, Los Angeles.